From yesterday’s Chromadex (sellers of Nicotinamide Riboside “NR” (FAQs) (Reviews)) earnings call:

Rob Fried – CEO, Chromadex

“We are very much looking forward to seeing the data on the long COVID study that Harvard has been doing. We know that they have completed the actual study. But it’s a blinded study. We have not yet seen the data. We’re excited to see that.

We’re also excited about the Parkinson’s study, which should be concluded — we thought it would be done in December. It’s obviously going to get done a little later than that, probably first quarter of next year. But it’s fully recruited. It’s just all those participants are taking a gram a day for a year. So we probably won’t see the data until sometime probably the first half of next year. But obviously, we’re very, very excited about that study as well.

There’s also other work that we’re doing in the orphan disease category. These diseases like Ataxia and Cockayne Syndrome that we’re very excited about and we think are important for us for later in this year”

Related:

FOLLOW us on Twitter @RaisingNAD